Targeting ATR in DNA damage response and cancer therapeutics
- 15 April 2013
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 40 (1), 109-117
- https://doi.org/10.1016/j.ctrv.2013.03.002
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK, the Medical Research Council, the Oxford Cancer Imaging Centre
- NIHR Biomedical Research Centre, Oxford
This publication has 114 references indexed in Scilit:
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiationCell Death & Disease, 2012
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapyCell Death & Differentiation, 2011
- The role of PARP in DNA repair and its therapeutic exploitationBritish Journal of Cancer, 2011
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugsMolecular Oncology, 2011
- ATR Autophosphorylation as a Molecular Switch for Checkpoint ActivationMolecular Cell, 2011
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesBritish Journal of Cancer, 2011
- The ATR barrier to replication-born DNA damageDNA Repair, 2010
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Deletion of the Developmentally Essential Gene ATR in Adult Mice Leads to Age-Related Phenotypes and Stem Cell LossCell Stem Cell, 2007